Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
SPAG9 is a further new antigen that might be a candidate for clinical use. In particular the high frequency of mRNA expression in different solid tumours and haematological malignancies is a prerequisite for a potentially wide use. Most of the tested CML patients showed humoral immune responses against SPAG9. Nevertheless, specific CD8-positive T cell-responses and clinical efficacy analogue to the targets RHAMM or WT-1 have to be shown.